Compare Snowflake Inc (SNOW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs BIO-TECHNE Corp — how do they compare? Snowflake Inc trades at $345.11 (market cap $117.43B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Snowflake Inc is far larger — about 10.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Snowflake Inc for 54 Days and BIO-TECHNE Corp for 63 Days on average.
| SNOW | TECH | |
|---|---|---|
Market Cap | $117.43B | $11.37B |
Volume | 2,441,528 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $356.47 | $72.61 |
52-Week Low | $121.11 | $43.31 |
Typical Hold Time | 54 Days | 63 Days |
Enterprise Value | $117.85B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNOW trades at $343.4, up 2.22% on the day, with a neutral technical signal and bullish moving averages. Revenue growth is strong, reaching $3.63B in 2025, but the company remains unprofitable with a net income margin of -20.07%. Recent news highlights a $3.75B convertible note offering and positive analyst coverage, with 81% of analysts rating it a Buy and a consensus price target of $418.03.
The outlook is mixed: robust revenue expansion and strategic partnerships offer upside, but persistent losses, high valuation multiples, and dilution risks from the note issuance pose significant challenges. Investor sentiment is cautiously optimistic, hinging on future profitability improvements.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
